Scientific publications

The C5a/C5aR1 axis promotes migration of tolerogenic dendritic cells to lymph nodes, impairing the anticancer immune response

Mar 4, 2025 | Magazine: Cancer Immunology Research

Yaiza Senent 1 2 3, Ana Remírez 1 3 4, David Repáraz 3 5 6, Diana Llopiz 3 5 6, Daiana P Celias 7, Cristina Sainz 1 2 4, Rodrigo Entrialgo-Cadierno 1 3 4, Lucia Suarez 2, Ana Rouzaut 2 3, Diego Alignani 3 4 8, Beatriz Tavira 1, John D Lambris 9, Trent M Woodruff 10, Carlos E de Andrea 11, Brian Ruffell 7 12, Pablo Sarobe 3 5 6, Daniel Ajona 1 2 3 4, Ruben Pio 1 2 3 4


Abstract

The precise mechanisms by which the complement system contributes to the establishment of an immunosuppressive tumor microenvironment and promotes tumor progression remain unclear. In this study, we investigated the expression and function of complement C5a receptor 1 (C5aR1) in human and mouse cancer-associated dendritic cells (DC). First, we observed an overexpression of C5aR1 in tumor-infiltrating DCs, compared with DCs from the blood or spleen. C5aR1 expression was restricted to type 2 conventional DCs and monocyte-derived DCs, which displayed a tolerogenic phenotype capable of inhibiting T-cell activation and promoting tumor growth. C5aR1 engagement in DCs drove their migration from tumors to tumor-draining lymph nodes, where C5a levels were higher. We used this knowledge to optimize an anticancer therapy aimed at enhancing DC activity. In three syngeneic tumor models, C5aR1 inhibition significantly enhanced the efficacy of poly I:C, a Toll-like receptor 3 agonist, in combination with PD-1/PD-L1 blockade. The contribution of C5aR1 inhibition to the antitumor activity of the combination treatment relied on type 1 conventional DCs and antigen-specific CD8+ T cells, required lymphocyte egress from secondary lymphoid organs, and was associated with an increase in IFNγ signaling. In conclusion, our study highlights the importance of the C5a/C5aR1 axis in the biology of cancer-associated DCs and provides compelling evidence for the therapeutic potential of modulating the complement system to enhance DC-mediated immune responses against tumors.

CITA DEL ARTÍCULO Cancer Immunol Res. 2025 Mar 4;13(3):384-399. doi: 10.1158/2326-6066.CIR-24-0250.

Our authors

Ana Remírez Sanz de Acedo
Cristina Sainz
David Repáraz Pernaut
Dr. Diana Llópiz Khatchikian
Diego Alignani
Laboratory technician Cytometry Platform
Dr. Beatriz Tavira Iglesias
Dr. Daniel Ajona Martínez-Polo